List of Stem Cells Companies in Israel - 11

BioGenCell was founded with the vision of developing safe, effective, and long-lasting effective treatment for incurable, blood vessel diseases that will be both accessible and patient friendly. Our disruptive TRACT technology platform provides a comprehensive approach for rapid manufacturing and commercialization of cell-therapies.

Biokine Therapeutics is a private biopharmaceutical company founded in 2000. Biokine lead product BKT140/BL8040, is a high affinity, long-acting CXCR4 receptor inhibitor that already passed successful Phase III for Stem Cell Mobilization and Phase I/II for Immunotherapy for cancer together with immune check point inhibitor Pembrolizumab (Keytruda, Merck) and Atezolizumab (Tecentriq, Genentech/Roche). BL8040 was licensed to BiolineRx and is being developed in the clinic together with BiolineRx Ltd. (NASDAQ:BLRX). Biokine has also developed a suite of unique technologies, MigHit™ – which is a phenotypic screen that allows identification of small molecules targeting migration and survival pathways in cancer and ImmunHit™ which is platform technology enables identification of small molecules targeting IFN-g mediated immune response in cancer and inflammation.

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

At Gamida Cell, we are striving to enable patients with blood cancers and serious blood disorders to reach cures through advanced cell therapy. We work with a sense of urgency and deeply held responsibility to address the clear need for new treatment options. And we believe that cell therapies should be available to patients who can benefit from them.

NeuroKaire by Genetika+ a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. NeuroKaire uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Kadimastem (TASE:KDST) A clinical stage biotech company introducing a cutting-edge TECHNOLOGY PLATFORM for the Development, Manufacturing, and Bio-Banking of functional human cells, providing OFF-THE-SHELF TREATMENT for multiple indications featuring ALS and Type 1 Diabetes as our top two leading projects.

NeuroKaire is a precision psychiatry and neurology company using a cutting-edge combination of stem-cell technology, genomics, and AI for treatment optimization and effective drug development. NeuroKaire uses this innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

NewStem is a biopharmaceutical company focused on Human Pluripotent Stem Cells (HPSCs) in general and Human Haploid Pluripotent Stem Cells (HHPSCs) in particular. These cells have the potential to change the face of medical research as they hold a pivotal role in regenerative medicine, disease therapy and cancer research. NewStem possesses pioneering intellectual property, reagents and experience related to the isolation and differentiation of HPSCs, their genetic manipulation, immunogenicity, tumorigenicity and their unique capacity in disease modeling. With this innovative research, and specialized drug and gene screening capabilities. NewStem is currently the only company worldwide to develop products based on this paradigm changing proprietary tech-nology, licensed from Yissum, Hebrew University’s technology transfer company, based on the findings and in-ventions of Prof. Nissim Benvenisty, of the Azrieli Center for Stem Cells and Genetic Research, The Hebrew University of Jerusalem.

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production.

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.